The effectiveness of Genentech and Roche’s (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin’s approval for treating GBM.
Patients with this genetic variant are more likely to experience adverse drug reactions or failure of treatment.
Seaside Therapeutics reported encouraging results from the largest randomized study conducted to date in patients with Fragile X syndrome.
An experimental drug from Nektar Therapeutics was able to shrink tumors and reduce a cancer biomarker in women with advanced ovarian cancer in a mid-stage study.
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
The recommendation caused a 64 percent jump in InterMune stock prices and fueled speculation that the Brisbane, Calif.-based company is ripe for acquisition.
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
On 11/19/09, the Company announced positive results in a pilot clinical study which included Prelude skin preparation and the placement of 10 Symphony tCGM biosensors on subjects with Type 1 or Type 2 Diabetes.
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.
Copyright © 2025 | WordPress Theme by MH Themes